These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 22344548)

  • 1. The pharmacological profile and clinical use of mesalazine (5-aminosalicylic acid).
    Klotz U
    Arzneimittelforschung; 2012 Feb; 62(2):53-8. PubMed ID: 22344548
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug insight: aminosalicylates for the treatment of IBD.
    Nielsen OH; Munck LK
    Nat Clin Pract Gastroenterol Hepatol; 2007 Mar; 4(3):160-70. PubMed ID: 17339853
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Review article: delivery and efficacy of topical 5-aminosalicylic acid (mesalazine) therapy in the treatment of ulcerative colitis.
    Harris MS; Lichtenstein GR
    Aliment Pharmacol Ther; 2011 May; 33(9):996-1009. PubMed ID: 21385194
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mesalazine for the treatment of inflammatory bowel disease.
    Criscuoli V; Modesto I; Orlando A; Cottone M
    Expert Opin Pharmacother; 2013 Aug; 14(12):1669-78. PubMed ID: 23767798
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The metabolism of mesalamine and its possible use in colonic diverticulitis as an anti-inflammatory agent.
    Cohen HD; Das KM
    J Clin Gastroenterol; 2006 Aug; 40 Suppl 3():S150-4. PubMed ID: 16885699
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral mesalazine for the treatment of Crohn's disease: clinical efficacy with respect to pharmacokinetic properties.
    Tromm A; Griga T; May B
    Hepatogastroenterology; 1999; 46(30):3124-35. PubMed ID: 10626173
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Encapsulated mesalamine granules (Apriso) for ulcerative colitis.
    Med Lett Drugs Ther; 2009 May; 51(1312):38-9. PubMed ID: 19448588
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Controversies with aminosalicylates in inflammatory bowel disease.
    Lim WC; Hanauer SB
    Rev Gastroenterol Disord; 2004; 4(3):104-17. PubMed ID: 15359211
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 5-Aminosalicylic acid derivatives. Clinical and pharmaceutical evaluation.
    Christensen LA; Jacobsen BA
    Neth J Med; 1989 Jun; 35 Suppl 1():S3-10. PubMed ID: 2702310
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [5-aminosalicylic acid in the treatment of ulcerative colitis and Crohn's disease].
    Moum B
    Tidsskr Nor Laegeforen; 2003 Sep; 123(18):2565-7. PubMed ID: 14714043
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 5-aminosalicylate is not chemoprophylactic for colorectal cancer in IBD: a population based study.
    Bernstein CN; Nugent Z; Blanchard JF
    Am J Gastroenterol; 2011 Apr; 106(4):731-6. PubMed ID: 21407180
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MMX mesalazine for the induction of remission of mild-to-moderately active ulcerative colitis: efficacy and tolerability in specific patient subpopulations.
    Lichtenstein GR; Kamm MA; Sandborn WJ; Lyne A; Joseph RE
    Aliment Pharmacol Ther; 2008 Jun; 27(11):1094-102. PubMed ID: 18363894
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Putting rectal 5-aminosalicylic acid in its place: the role in distal ulcerative colitis.
    Marshall JK; Irvine EJ
    Am J Gastroenterol; 2000 Jul; 95(7):1628-36. PubMed ID: 10925961
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multiparticulate systems containing 5-aminosalicylic acid for the treatment of inflammatory bowel disease.
    Bautzová T; Rabišková M; Lamprecht A
    Drug Dev Ind Pharm; 2011 Sep; 37(9):1100-9. PubMed ID: 21417610
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug therapy: dose-response relationship of oral mesalazine in inflammatory bowel disease.
    Mulder CJ; van den Hazel SJ
    Mediators Inflamm; 1998; 7(3):135-6. PubMed ID: 9705596
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Topical delivery of therapeutic agents in the treatment of inflammatory bowel disease.
    Klotz U; Schwab M
    Adv Drug Deliv Rev; 2005 Jan; 57(2):267-79. PubMed ID: 15555742
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 5-Aminosalicylic acid containing drugs. Delivery, fate, and possible clinical implications in man.
    Christensen LA
    Dan Med Bull; 2000 Feb; 47(1):20-41. PubMed ID: 10709142
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inducing and maintaining remission in ulcerative colitis: role of high-dose, extended-release mesalamine.
    Kao J; Kwok K; Das KM
    J Clin Gastroenterol; 2010 Sep; 44(8):531-5. PubMed ID: 20495466
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of 5-aminosalicylic acid (5-ASA) for cancer chemoprevention: lack of efficacy against nascent adenomatous polyps in the Apc(Min) mouse.
    Ritland SR; Leighton JA; Hirsch RE; Morrow JD; Weaver AL; Gendler SJ
    Clin Cancer Res; 1999 Apr; 5(4):855-63. PubMed ID: 10213222
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Will a 5-ASA a day keep the cancer (and dysplasia) away?
    Rubin DT; Lashner BA
    Am J Gastroenterol; 2005 Jun; 100(6):1354-6. PubMed ID: 15929769
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.